Josh Peterson Archives
Nov. 18, 2020—Josh Peterson, MD, MPH, professor of Biomedical Informatics and Medicine, has been named director of the Center for Precision Medicine at Vanderbilt University Medical Center, effective since Oct. 1. The center is VUMC’s hub for interdisciplinary research in precision medicine. Housed within the Department of Biomedical Informatics, it was founded in 2015 by Joshua Denny,...
Nov. 5, 2020—Population-wide screening for genetic variants linked to hereditary breast and ovarian cancer may be cost effective in women between the ages of 20 and 35, according to a study published in JAMA Network Open.
Jul. 1, 2020—With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants’ relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes.
Oct. 17, 2019—Josh Peterson, MD, MPH, and Dan Roden, MD, are among 10 leaders in clinical pharmacology and translational medicine recognized this week by the American Society for Clinical Pharmacology and Therapeutics.
Jul. 25, 2019—A national study is seeking to determine whether genetic testing can help physicians choose the best drugs for their patients to relieve pain and depression.
Jan. 25, 2018—Vanderbilt University Medical Center (VUMC) has expanded and relaunched genetic testing to predict patient responses to drugs.
Mar. 31, 2016—A new clinical implementation study from Vanderbilt University Medical Center measures how physicians have responded to the introduction of routine genetic testing to predict patient response to the commonly prescribed antiplatelet drug clopidogrel.
Jun. 25, 2015—A new program being offered this fall through Vanderbilt University School of Medicine will offer health care professionals the opportunity to earn a master’s degree in the growing biomedical informatics field.
Oct. 17, 2013—A research team led by Josh Peterson, M.D., MPH, assistant professor of Biomedical Informatics and Medicine, and John Graves, Ph.D., assistant professor of Preventive Medicine, will study the cost-effectiveness of testing patients’ risk of adverse gene-drug interactions.